Brain Tumours

Brain tumours are a type of abnormal growth or mass that can develop in the brain or central nervous system. These tumours can vary greatly in size, location, and type and present a variety of symptoms that can have a significant impact on a person’s quality of life. While some brain tumours are benign and easily treatable, others can be malignant and life-threatening, making the study and treatment of these tumours an important area of research and clinical practice. The incidence of brain tumours varies across populations, with some demographic groups and geographic regions showing higher rates of occurrence. Factors such as age, gender, and genetic predispositions can also play a role in the development of brain tumours. Diagnosis of brain tumours often involves a range of imaging and diagnostic tests, including MRI and CT scans, as well as biopsy and other laboratory analyses. Treatment of brain tumours can involve a range of interventions, including surgery, radiotherapy, chemotherapy, and targeted therapy. The selection of treatment depends on various factors, including the type and location of the tumour, as well as the overall health of the patient. For some patients, treatment may involve a combination of these interventions, as well as supportive care and symptom management. While much progress has been made in the diagnosis and treatment of brain tumours, there is still a lot to be learned about these complex and challenging conditions. Ongoing research into the causes, risk factors, and underlying biology of brain tumours is critical to improving patient outcomes and advancing our understanding of these important conditions.

Gliomas: These tumours originate in the glial cells of the brain and can be either low-grade or high-grade.
Meningiomas: These tumours arise from the membranes that cover the brain and spinal cord and are often slow-growing.
Pituitary adenomas: These tumours develop in the pituitary gland, which is located at the base of the brain, and can cause hormonal imbalances.
Schwannomas: These tumours are formed from Schwann cells, which wrap around nerve fibres and are often benign.
Craniopharyngiomas: These tumours develop near the pituitary gland and can cause various symptoms, including headaches and vision problems.
Medulloblastomas: These tumours develop in the cerebellum, which is responsible for coordination and balance. They are more common in children.
Astrocytomas: These tumours develop from astrocytes, which are a type of glial cell. They can be low-grade or high-grade.
Oligodendrogliomas: These tumours develop from oligodendrocytes, which produce the myelin sheath that insulates nerve fibres in the brain. They are often slow-growing.

Gliomas

Gliomas are a type of brain tumour that arise from the glial cells of the central nervous system. They are the most common type of primary brain tumour in adults, accounting for approximately 80% of all malignant brain tumours. Glial cells, also known as neuroglia or simply glia, are non-neuronal cells that provide structural and functional support to the neurones in the brain and nervous system. There are several types of glial cells, including astrocytes, oligodendrocytes, and microglia, each with their own unique functions. Unlike neurones, which are specialised cells that transmit electrical and chemical signals in the brain, glial cells do not have the ability to generate or propagate action potentials. Instead, they play important roles in maintaining the proper environment for neuronal function, regulating neurotransmitter levels, and providing physical support to neurones. Astrocytes, for example, are star-shaped cells that provide structural support to neurones and help to maintain the proper balance of ions, nutrients, and other substances in the brain. Oligodendrocytes produce myelin, a fatty substance that surrounds and insulates axons to help speed up the transmission of signals between neurones. Microglia are immune cells that help protect the brain from infections and injuries. The incidence of gliomas varies by age, with higher rates observed in older individuals. The average age at diagnosis for gliomas is around 45–60 years, and they are more common in men than in women. Gliomas can be divided into several subtypes, including astrocytomas, oligodendrogliomas, and ependymomas, each with different clinical characteristics and outcomes. Survival rates for gliomas depend on several factors, including the location, size, and grade of the tumour, as well as the age and overall health of the patient. The 5-year survival rate for all gliomas is approximately 33%, but the figure varies widely depending on the subtype of glioma. For example, low-grade astrocytomas and oligodendrogliomas have better long-term survival rates than high-grade gliomas such as glioblastomas. The primary modes of treatment for gliomas include surgical resection, radiation therapy, and chemotherapy. Surgery is often the first-line treatment for gliomas, and it can involve partial or complete removal of the tumour. Radiation therapy is commonly used in conjunction with surgery to kill remaining tumour cells and prevent a recurrence. Chemotherapy can also be used in certain cases, either alone or in combination with other treatments, it may be administered orally or intravenously. Despite recent advances in diagnosis and treatment, the prognosis for patients with gliomas remains variable and challenging, with a lot depending on the location of the tumour. The development of new treatment approaches and therapies, as well as ongoing research into the underlying biology of gliomas, is critical to improving outcomes for patients with these complex and often life-threatening tumours.

Meningiomas

Meningiomas are a type of primary brain tumour that arise from the meninges, the membranes that cover and protect the brain and spinal cord. They are typically slow-growing and usually benign, accounting for approximately 15–20% of all primary brain tumours. Meningiomas can occur in individuals of any age but are most common in adults, with a higher incidence in women. They can be categorised as either grade I (benign), grade II (atypical), or grade III (anaplastic), depending on their histological characteristics and rate of growth. The prognosis for meningiomas is generally good, with 5-year survival rates ranging from 80-90% for grade I tumours to 50-70% for grade II tumours. The long-term outlook for individuals with meningiomas depends on several factors, including the location and size of the tumour, as well as the age and overall health of the patient. In cases where the tumour is small and asymptomatic, a “watch and wait” approach may be taken, with periodic imaging to monitor for changes. Treatment options for meningiomas include surgical resection, radiation therapy, and in some cases, chemotherapy. Surgery is often the first-line treatment for meningiomas and can involve complete or partial removal of the tumour. Radiation therapy may be used in conjunction with surgery or as the primary treatment for tumours that are not amenable to surgery. Chemotherapy is typically reserved for more aggressive or recurrent tumours.

Pituitary adenomas

Pituitary adenomas are a type of tumour that develops in the pituitary gland, a small gland located at the base of the brain. It plays a critical role in regulating hormone production and release. These tumours are typically benign and slow-growing, and they account for approximately 10–15% of all intracranial neoplasms. The incidence of pituitary adenomas varies by age and gender, with higher rates observed in women and older individuals. They can be classified based on their size and hormone production, with functioning adenomas producing excess hormones and non-functioning adenomas not producing any hormones. Pituitary adenomas that produce excess growth hormone can cause a condition known as acromegaly, which is characterised by abnormal bone growth in the hands, feet, and face. This condition can occur in both adults and children and may lead to a condition called gigantism in young individuals if the tumour develops before the closure of the growth plates. In cases of gigantism, the overproduction of growth hormone causes excessive linear growth, resulting in a significantly increased height and body size. If left untreated, gigantism can lead to significant health complications, including joint pain, cardiovascular disease, and reduced life expectancy. While pituitary adenomas are a common cause of acromegaly and gigantism, not all pituitary adenomas produce growth hormones. Some adenomas may produce other hormones or no hormones at all, and their clinical manifestations will depend on the type of hormone produced and the function of the gland. Therefore, a thorough evaluation by a qualified medical professional is necessary to determine the underlying cause of any growth abnormalities. The prognosis for pituitary adenomas is generally good, with a 5-year survival rate of approximately 95%. The long-term outlook for individuals with pituitary adenomas depends on several factors, including the size and location of the tumour, as well as the presence of hormone overproduction and associated symptoms. Treatment options for pituitary adenomas include surgical resection, radiation therapy, and medical therapy. Surgery is often the first-line treatment for pituitary adenomas and can involve transsphenoidal or transcranial approaches. Radiation therapy may be used in cases where the tumour is not amenable to surgery or as an adjunct to surgery to control residual tumours. Medical therapy may be used to manage hormone overproduction and associated symptoms and can include dopamine agonists, somatostatin analogues, and other medications.

Schwannomas

Schwannomas, also known as neurilemmomas, are typically benign tumours that arise from Schwann cells, which are specialised cells that produce the myelin sheath that covers nerve fibres. Schwannomas are most commonly found in the peripheral nervous system but can also occur in the central nervous system. Schwann cells are specialised cells that produce the myelin sheath that covers nerve fibres in the peripheral nervous system. They are responsible for supporting and protecting neurones, as well as facilitating the rapid transmission of electrical signals between neurones. Schwann cells are also involved in the regeneration of nerve fibres following injury or damage. These cells are named after the German physiologist Theodor Schwann, who first described them in the mid-19th century. Schwann cells are a type of glial cell, which are non-neuronal cells that provide support and protection to neurones in the nervous system. The incidence of schwannomas is relatively low, with an estimated incidence of 0.3 per 100,000 individuals. While these tumours are generally benign, they can cause symptoms if they compress nearby nerves or other structures. Symptoms may include pain, numbness, tingling, or weakness in the affected area. The prognosis for schwannomas is generally good, with a reported 5-year survival rate of over 95%. The majority of schwannomas are treated with surgical resection, which involves removing the tumour and any affected surrounding tissue. In cases where the tumour is located in a particularly sensitive area of the body, such as the spinal cord, radiation therapy may also be used to reduce its size and relieve symptoms. While schwannomas are generally benign, a small percentage may become malignant and develop into a cancer known as malignant peripheral nerve sheath tumour (MPNST). MPNSTs are rare and aggressive tumours that can be difficult to treat. It is important for individuals with schwannomas to be closely monitored by a qualified medical professional to detect any potential changes in the tumour’s behaviour.

Craniopharyngiomas

Craniopharyngiomas are rare and benign tumours that develop near the pituitary gland at the base of the brain. These tumours are thought to arise from remnants of embryonic tissue that normally form the connection between the developing brain and the mouth. The exact cause of craniopharyngiomas is unknown. Craniopharyngiomas can occur at any age, but they most commonly affect children and young adults. The incidence of craniopharyngiomas is estimated to be approximately 1 in every 1 million individuals per year. The prognosis for individuals with craniopharyngiomas depends on several factors, including the size and location of the tumour, the age of the individual, and the presence of any associated medical conditions. The overall 5-year survival rate for individuals with craniopharyngiomas is approximately 80%. The primary modes of treatment for craniopharyngiomas include surgery and radiation therapy. Surgical removal of the tumour is the preferred treatment option when possible, as it can provide the best chance of long-term control of the disease. In some cases, radiation therapy may be used as a primary treatment or in conjunction with surgery to help control the growth and spread of the tumour. Hormone replacement therapy may also be required to manage any endocrine disorders that may arise as a result of damage to the pituitary gland. While craniopharyngiomas are generally benign tumours, they can cause significant symptoms due to their location in the brain. These symptoms may include headaches, vision changes, hormonal imbalances, and cognitive impairment. It is important for individuals with craniopharyngiomas to be closely monitored by a qualified medical professional to manage these symptoms and detect any potential changes in the tumour’s behaviour.

Medulloblastomas

Medulloblastomas are malignant brain tumours that primarily affect children, although they can also occur in adults. These tumours originate in the cerebellum, the part of the brain that controls movement and balance. Medulloblastomas are relatively rare, accounting for approximately 20% of all paediatric brain tumours. The incidence of medulloblastomas is estimated to be approximately 0.5 to 0.7 per 100,000 children per year. The prognosis for individuals with medulloblastomas depends on several factors, including the age of the individual, the size and location of the tumour, and the presence of any associated medical conditions. The overall 5-year survival rate for individuals with medulloblastomas is approximately 70%. The primary modes of treatment for medulloblastomas include surgery, radiation therapy, and chemotherapy. Surgery is used to remove as much of the tumour as possible, while radiation therapy and chemotherapy are used to kill any remaining cancer cells. Depending on the individual case, a combination of these treatments may be used. Medulloblastomas can cause a range of symptoms, including headaches, nausea, vomiting, and problems with coordination and balance. These symptoms can be managed with medication and other therapies.

Astrocytomas

Astrocytomas are a type of brain tumour that develops from astrocytes, a type of glial cell in the brain that provides structural and nutritional support to nerve cells. Astrocytomas are the most common type of primary brain tumour, accounting for approximately 75% of all adult brain tumours. Astrocytes are a type of glial cell that are found in the central nervous system, including the brain and spinal cord. They are star-shaped cells that provide structural and nutritional support to nerve cells, as well as help to maintain the blood-brain barrier. Astrocytes are also involved in repairing damage to the brain and spinal cord and play a role in regulating the chemical environment of the brain. Dysfunction or abnormal proliferation of astrocytes has been implicated in a variety of neurological disorders, including brain tumours and neurodegenerative diseases. The incidence of astrocytomas varies depending on the grade of the tumour, with higher-grade tumours being less common. Low-grade astrocytomas are more commonly found in young adults and children, whereas high-grade astrocytomas are more common in older adults. The prognosis for individuals with astrocytomas also varies depending on the grade of the tumour. Low-grade astrocytomas have a better prognosis, with a 5-year survival rate of approximately 80-90%, while high-grade astrocytomas have a poorer prognosis, with a 5-year survival rate of approximately 15-20%. The primary modes of treatment for astrocytomas include surgery, radiation therapy, and chemotherapy. The choice of treatment depends on the grade of the tumour, its location in the brain, and the individual case. Symptoms of astrocytomas can vary depending on the location and size of the tumour but may include headaches, seizures, changes in vision or hearing, weakness or numbness in the limbs, and cognitive changes. These symptoms can be managed with medication and other therapies.

Oligodendrogliomas

Oligodendrogliomas are a type of brain tumour that develops from oligodendrocytes, a type of glial cell in the brain that produces the myelin sheath that surrounds and insulates nerve fibres. Oligodendrogliomas account for approximately 4-5% of all primary brain tumours. Oligodendrocytes are a type of glial cell in the central nervous system that are responsible for producing the myelin sheath that surrounds and insulates nerve fibres. The myelin sheath facilitates the efficient conduction of nerve impulses and is essential for proper neural function. Dysfunction or loss of oligodendrocytes has been implicated in a variety of neurological disorders, including multiple sclerosis and leukodystrophies. Oligodendrocytes are also involved in regulating the chemical environment of the brain and play a role in repairing damage to the nervous system. Research into oligodendrocytes and their role in neurological function and disease is ongoing and may lead to the development of new treatments for these conditions. The incidence of oligodendrogliomas is relatively low, with most cases occurring in middle-aged adults. These tumours are most commonly found in the frontal and temporal lobes of the brain. The prognosis for individuals with oligodendrogliomas varies depending on the grade of the tumour. Low-grade oligodendrogliomas have a better prognosis, with a 5-year survival rate of approximately 70-90%, while high-grade oligodendrogliomas have a poorer prognosis, with a 5-year survival rate of approximately 25-30%. The primary modes of treatment for oligodendrogliomas include surgery, radiation therapy, and chemotherapy. The choice of treatment depends on the grade of the tumour, its location in the brain, and the individual case. Symptoms of oligodendrogliomas can vary depending on the location and size of the tumour but may include seizures, headaches, changes in vision or hearing, weakness or numbness in the limbs, and cognitive changes.

Resources and Support – United Kingdom

Here is a list of UK-based organisations, charities and clubs that provide support and information to patients with brain tumours and their families, along with their website links:

1. The Brain Tumour Charity: a national charity that provides support and information to patients and families affected by brain tumours. Website: https://www.thebraintumourcharity.org/
2. HeadSmart: an initiative that aims to improve the diagnosis and outcomes of childhood brain tumours by raising awareness of the signs and symptoms of the disease. Website: https://www.headsmart.org.uk/
3. Brainstrust: a charity that provides information and support to people with brain tumours, including a helpline, online forum, and support groups. Website: https://brainstrust.org.uk/
4. Macmillan Cancer Support: a national charity that provides information and support to people affected by cancer, including those with brain tumours. Website: https://www.macmillan.org.uk/
5. The National Brain Appeal: a charity that raises funds for research and treatment of neurological disorders, including brain tumours. Website: https://www.nationalbrainappeal.org/

The Brain Tumour Research Centre: a research centre/charity dedicated to brain tumour research and awareness. Website: https://www.btrc-charity.org/
Brainwaves: a charity providing support and information to children and young people (and their families). Website: https://www.brainwaves.org.uk/
The Brain Tumour Support Group: support and information for patients and families affected by brain tumours. Website: https://www.braintumoursupport.co.uk/

Resources and Support – USA

Here are some organisations, charities and clubs that patients with brain tumours and their families can go to for support and information in the USA:

American Brain Tumour Association: resources for patients and families, including support groups and conferences. Website: https://www.abta.org/
National Brain Tumour Society: support, education, research, and advocacy. Website: https://braintumor.org/
Brain Tumour Foundation: educational resources, support groups, and patient navigation. Website: https://braintumorfoundation.org/
Children’s Brain Tumour Foundation: resources and support for families. Website: https://www.cbtf.org/
Head for the Cure: awareness and fundraising for brain cancer research. Website: https://www.headforthecure.org/
The Musella Foundation: clinical trial information and support groups. Website: https://virtualtrials.org/

Resources and Support – India

Here is a list of organisations, charities, and support groups in India for patients with brain tumours and their families:

1. Indian Cancer Society – Support services and information for people affected by cancer. Website: https://indiancancersociety.org/
2. Brain Tumour Foundation – Information and support (India). Website: http://www.braintumorfoundation.in/
3. Cancer Patients Aid Association – Support services and financial assistance. Website: https://cancer.org.in/
4. CanSupport – Delhi-based nonprofit offering counselling and home-based care support. Website: https://cansupport.org/
5. Indian Society of Neuro-Oncology – Professional society for neuro-oncology. Website: https://www.isno.in/

It is important to note that this is not an exhaustive list, and there may be other organisations, charities, and support groups available in India for brain tumour patients and their families.